NeuroKaire
About
NeuroKaire transforms depression medication selection by understanding how each patient's unique brain and body responds to medication, moving beyond trial-and-error. Their service helps evaluate how different antidepressants are likely to interact with a person's brain biology before treatment starts, guiding treatment choices with greater confidence. NeuroKaire serves both patients and providers.
Key facts
At-a-glance profile data
- Website
- genetikaplus.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2017
- Employees
- 36
- Total funding
- $27M (Grant)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 31 Jul 2022 | Grant | $17M | European Commission’s European Innovation Council |
| 11 Oct 2021 | Series A | $10M | - |
Tech stack
Detected on genetikaplus.com, last scanned 19 Sept 2026. Run your own scan
- Email provider
- Google Workspace
Add first review
Frequently asked
How much funding has NeuroKaire raised?
NeuroKaire has raised a total of $27M in funding. The most recent round on record is Grant.
How many employees does NeuroKaire have?
NeuroKaire has approximately 36 people on record.